ERBB2 and breast carcinoma: As mentioned above, eribulin has shown efficacy in HER2-negative metastatic breast cancer that is resistant to AT therapy, and eribulin could be an effective treatment option for high-risk locally advanced breast cancer with a poor prognosis.